HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Howard Fillit, MD

Founding executive director and chief science officer, Alzheimer's Drug Discovery Foundation

Articles

Updates on the Diagnostics Accelerator, Future Goals of the ADDF: Howard Fillit, MD

February 01, 2022

The founding executive director of the Alzheimer’s Drug Discovery Foundation commented on ongoing developments from the organization, particularly the diagnostics accelerator, which aims at identifying a better way to diagnose Alzheimer disease. [WATCH TIME: 6 minutes]

The Development of Technology for Alzheimer Disease: Howard Fillit, MD

January 31, 2022

Discussing recent technological advancements in the AD field, the founding executive director of the Alzheimer’s Drug Discovery Foundation noted the doors that these innovations have opened. [WATCH TIME: 4 minutes]

Howard Fillit, MD: Aducanumab Findings Lead the Way in Dementia

May 20, 2020

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the landmark findings from Biogen on its agent aducanumab and the impact the trial might have on the future.

Howard Fillit, MD: Telemedicine and Tech in the Future Care of Alzheimer and Dementia

May 06, 2020

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation detailed what he foresees the future of Alzheimer and dementia care to look like with telemedicine as a more permanent aspect of care.

Howard Fillit, MD: The Positives of Telemedicine Adoption for Geriatric Patients

May 02, 2020

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation spoke to the way the COVID-19 pandemic has transformed the use of telemedicine for the elderly with conditions like Alzheimer and dementia.

Howard Fillit, MD: The Impact of COVID-19 in Alzheimer Disease

May 01, 2020

The founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation discussed the effect that the COVID-19 pandemic has had on the care of patients with Alzheimer disease and dementias.